Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boroda Supramolecular Active Zinc for Scalp Psoriasis
NCT04801433Completed
- Sponsor
- Xijing Hospital
- Start
- Nov 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of zinc in psoriasis (3 arms), sponsored by Xijing Hospital. Primary endpoints: Success rate at the end of treatment at 4 weeks and Total Sign Score at 4 weeks. Started Nov 2018; status: completed.
02
Drugs
zinc
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04801433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04801433.